Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial

Heinz Ludwig(Wilhelminen Hospital), R. Flener(Fraunhofer Austria), B.G.K. Van Camp, Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), E. Polli(University of Milan), M. Peetermans(Antwerp University Hospital), Werner Scheithauer(Comprehensive Cancer Center Vienna), Georges Fillet(University of Liège), R. Kuzmits(University of Vienna)
European Journal of Cancer and Clinical Oncology
September 1, 1986
10.1016/0277-5379(86)90015-5
Cited by 44

Related Papers

International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k